Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis
A Mor, MS Salto, A Katav, N Barashi… - Annals of the …, 2019 - ard.bmj.com
Annals of the Rheumatic Diseases, 2019•ard.bmj.com
Objectives We aimed to assess the expression of the CCL24 chemokine in systemic
sclerosis (SSc) and to evaluate the possible pathogenic implications of the CCL24/CCR3
axis using both in vitro and in vivo models. We further investigated the efficacy of an anti-
CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal
and pulmonary inflammation and fibrosis in experimental animal models. Methods We used
ELISA and fluorescence immunohistochemistry to determine CCL24 levels in serum and …
sclerosis (SSc) and to evaluate the possible pathogenic implications of the CCL24/CCR3
axis using both in vitro and in vivo models. We further investigated the efficacy of an anti-
CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal
and pulmonary inflammation and fibrosis in experimental animal models. Methods We used
ELISA and fluorescence immunohistochemistry to determine CCL24 levels in serum and …
Objectives
We aimed to assess the expression of the CCL24 chemokine in systemic sclerosis (SSc) and to evaluate the possible pathogenic implications of the CCL24/CCR3 axis using both in vitro and in vivo models. We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal and pulmonary inflammation and fibrosis in experimental animal models.
Methods
We used ELISA and fluorescence immunohistochemistry to determine CCL24 levels in serum and CCL24/CCR3 expression in skin biopsies of SSc patients. Skin fibroblasts and endothelial cells treated with CCL24 or SSc serum with or without CM-101 were used to follow cell activation and differentiation. Prevention and treatment in vivo bleomycin (BLM)-induced models were used to evaluate experimental dermal and pulmonary fibrosis progression following treatment with the CM-101 mAb.
Results
CCL24 circulating levels were significantly elevated in SSc patients. CCL24/CCR3 expression was strongly increased in SSc skin. Blockade of CCL24 with CM-101 significantly reduced the activation of dermal fibroblasts and their transition to myofibroblasts induced by SSc serum. CM-101 was also able to significantly inhibit endothelial cell activation induced by CCL24. In BLM-induced experimental animal models, CM-101 profoundly inhibited both dermal and pulmonary fibrosis and inflammation.
Conclusions
CCL24 plays an important role in pathological processes of skin and lung inflammation and fibrosis. Inhibition of CCL24 by CM-101 mAb can be potentially beneficial for therapeutic use in SSc patients.
ard.bmj.com